The art and science of running a successful pharmaceutical company.
 | November 18, 2009 By:Adam Farber, Kim Wagner, Ulrik Schulze
The business philosophy and tools that revolutionized Toyota could save the ailing drug industry a lot more than just time and money. But is pharma really capable of getting lean?
 |
November 11, 2009 By:George Koroneos, Online Content & News Editor
Following through with its promise to waste no time in merging Wyeth and Pfizer, the pharma giant announced restructuring plans for its global research network.
 |
November 11, 2009 By:Andrew Sheivachman
Developing countries will receive the scarce vaccine for free, as GSK remains confident it will fulfill contractual vaccine obligations around the world.
 |
November 9, 2009
This guide aims to provide pharma marketers with an overview of the key challenges surrounding Direct-to-Consumer (DTC) online marketing and some potential solutions for effectively leveraging this channel within the complex regulatory environment.
 |
November 4, 2009 By:Walter Armstrong, Senior Editor
A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
 |
 | November 4, 2009 By:Bassil Dahiyat
As the first generation of biologics patents expire, companies are jokeying for position in follow-on biologics.
 |
November 4, 2009 By:George Koroneos, Online Content & News Editor
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
 |
October 8, 2009 By:George Koroneos, Online Content & News Editor
Sure, industry growth is at "historically low levels," but at least pharma is still growing. The industry's market value should surpass $825 billion in 2010, and forecasted growth was bumped up one percentage point from original estimates.
 |
|